Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | PDE5A | O76074 | 6/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | VNN1 | O95497 | 2/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1715269 | 0.89 | HDAC1 (0.44) | TSHRHDAC1PDE5APDE4APDE4B | |
| SCHEMBL1715615 | 0.86 | POLB (0.44) | TSHRPDE5AHIF1ANPC1RAB9A | |
| SCHEMBL1715722 | 0.85 | TSHR (0.41) | TSHRPDE5APDCD1CD274RXFP1 | |
| SCHEMBL1714727 | 0.82 | KDR (0.42) | TSHRPDCD1CD274RXFP1AURKA | |
| SCHEMBL1715528 | 0.81 | KIT (0.49) | TSHRPDE5ARXFP1AURKAAURKB | |
| SCHEMBL1715301 | 0.81 | NPC1 (0.50) | TSHRHDAC1NPC1RAB9AAURKA | |
| SCHEMBL1714870 | 0.79 | TSHR (0.46) | TSHRPDE5AHIF1ANPC1RAB9A | |
| SCHEMBL1715441 | 0.79 | KDM4C (0.48) | PDE5AHIF1A | |
| SCHEMBL1714882 | 0.77 | POLB (0.44) | TSHRNPC1RAB9ACSF1R | |
| SCHEMBL1714967 | 0.77 | VNN1 (0.48) | HDAC1VNN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034811-B2 | Hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2011-10-11 | — | — | US | claimed |
| EP-1697312-B1 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2011-07-20 | — | — | EP | claimed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | claimed |
| JP-2007513098-A | — | — | 2007-05-24 | — | — | JP | claimed |
| CN-1906155-A | Novel hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA AS (DK) | 2007-01-31 | — | — | CN | claimed |
| EP-1697312-A2 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | claimed |
| WO-2005054179-A2 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2005-06-16 | — | — | WO | claimed |
| US-8034811-B2 | Hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| US-8034811-B2 | Hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| US-8034811-B2 | Hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| EP-1697312-B1 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2011-07-20 | — | — | EP | disclosed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | disclosed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | disclosed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | disclosed |
| CN-1906155-A | Novel hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA AS (DK) | 2007-01-31 | — | — | CN | disclosed |
| EP-1697312-A2 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005054179-A2 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | F9, F12, HDAC9 | TSHR 866/4885HDAC1 45/4885PDE5A 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.